Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Driving CARs Across New Borders.

Turtle CJ, Adair JE.

Hum Gene Ther. 2018 May;29(5):529. doi: 10.1089/hum.2018.29065.cjt. No abstract available.

PMID:
29715075
2.

Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.

Gauthier J, Turtle CJ.

Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3. Review.

PMID:
29625831
3.

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, Myerson D, Gonzalez-Cuyar L, Baldessari A, English C, Yu A, Zheng H, Furlan SN, Hunt DJ, Hoglund V, Finney O, Brakke H, Blazar BR, Berger C, Riddell SR, Gardner R, Kean LS, Jensen MC.

Cancer Discov. 2018 Jun;8(6):750-763. doi: 10.1158/2159-8290.CD-17-1368. Epub 2018 Mar 21.

PMID:
29563103
4.

CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.

Hay KA, Turtle CJ.

Immunotherapy. 2018 Feb 1;10(4):251-254. doi: 10.2217/imt-2017-0162. No abstract available.

PMID:
29421980
5.

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ.

Blood. 2018 Jan 4;131(1):121-130. doi: 10.1182/blood-2017-07-793760. Epub 2017 Oct 16.

PMID:
29038338
6.

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, Chung D, Harju-Baker S, Özpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ.

Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.

PMID:
29025771
7.

Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation.

Bhattacharyya A, Hanafi LA, Sheih A, Golob JL, Srinivasan S, Boeckh MJ, Pergam SA, Mahmood S, Baker KK, Gooley TA, Milano F, Fredricks DN, Riddell SR, Turtle CJ.

Biol Blood Marrow Transplant. 2018 Feb;24(2):242-251. doi: 10.1016/j.bbmt.2017.10.003. Epub 2017 Oct 9.

PMID:
29024803
8.

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G, Fry T, Chew A, Maloney DG, June CH.

Mol Ther. 2018 Jan 3;26(1):280-288. doi: 10.1016/j.ymthe.2017.09.008. Epub 2017 Sep 12.

PMID:
28970045
9.

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.

PMID:
28924019
10.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG.

J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.

PMID:
28715249
11.

Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.

Hay KA, Turtle CJ.

Drugs. 2017 Mar;77(3):237-245. doi: 10.1007/s40265-017-0690-8. Review.

12.

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG.

Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621.

13.

CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.

Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, Vukovic P, Munster DJ, Nagasaki T, Barnard RT, Mahler SM, Anguille SA, Berneman Z, Horvath LG, Bradstock KF, Joshua DE, Clark GJ, Hart DN.

Oncoimmunology. 2016 May 5;5(6):e1168555. doi: 10.1080/2162402X.2016.1168555. eCollection 2016 Jun.

14.

Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape.

Turtle CJ, Maloney DG.

Expert Rev Hematol. 2016 Aug;9(8):719-21. doi: 10.1080/17474086.2016.1203251. Epub 2016 Jul 4. No abstract available.

PMID:
27322438
15.

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.

Turtle CJ, Riddell SR, Maloney DG.

Clin Pharmacol Ther. 2016 Sep;100(3):252-8. doi: 10.1002/cpt.392. Epub 2016 Jun 17.

PMID:
27170467
16.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG.

J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.

17.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.

18.

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR.

Leukemia. 2016 Feb;30(2):492-500. doi: 10.1038/leu.2015.247. Epub 2015 Sep 15.

19.

Susceptibility of commonly used ferritin assays to the classic hook effect.

Ranjitkar P, Turtle CJ, Harris NS, Holmes DT, Pyle-Eilola A, Maloney DG, Greene DN.

Clin Chem Lab Med. 2016 Feb;54(2):e41-3. doi: 10.1515/cclm-2015-0604. No abstract available.

PMID:
26351953
20.

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ.

Cancer J. 2014 Mar-Apr;20(2):141-4. doi: 10.1097/PPO.0000000000000036. Review.

21.

Chimeric antigen receptor modified T cell therapy for B cell malignancies.

Turtle CJ.

Int J Hematol. 2014 Feb;99(2):132-40. doi: 10.1007/s12185-013-1490-x. Epub 2013 Dec 14. Review.

PMID:
24338745
22.

HLA engineering of human pluripotent stem cells.

Riolobos L, Hirata RK, Turtle CJ, Wang PR, Gornalusse GG, Zavajlevski M, Riddell SR, Russell DW.

Mol Ther. 2013 Jun;21(6):1232-41. doi: 10.1038/mt.2013.59. Epub 2013 Apr 30.

23.

Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.

McGoldrick SM, Bleakley ME, Guerrero A, Turtle CJ, Yamamoto TN, Pereira SE, Delaney CS, Riddell SR.

Blood. 2013 Apr 4;121(14):2796-803. doi: 10.1182/blood-2012-09-453720. Epub 2013 Feb 14.

24.
25.

Engineered T cells for anti-cancer therapy.

Turtle CJ, Hudecek M, Jensen MC, Riddell SR.

Curr Opin Immunol. 2012 Oct;24(5):633-9. doi: 10.1016/j.coi.2012.06.004. Epub 2012 Jul 18. Review.

26.

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.

Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR.

Blood. 2012 Jan 5;119(1):72-82. doi: 10.1182/blood-2011-07-366419. Epub 2011 Oct 26.

27.

Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cells.

Turtle CJ, Delrow J, Joslyn RC, Swanson HM, Basom R, Tabellini L, Delaney C, Heimfeld S, Hansen JA, Riddell SR.

Blood. 2011 Sep 8;118(10):2752-62. doi: 10.1182/blood-2011-02-334698. Epub 2011 Jul 25.

28.

HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.

Chapuis AG, Casper C, Kuntz S, Zhu J, Tjernlund A, Diem K, Turtle CJ, Cigal ML, Velez R, Riddell S, Corey L, Greenberg PD.

Blood. 2011 May 19;117(20):5391-402. doi: 10.1182/blood-2010-11-320226. Epub 2011 Mar 21.

29.

Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.

Turtle CJ, Riddell SR.

Curr Opin Immunol. 2011 Apr;23(2):299-305. doi: 10.1016/j.coi.2010.12.012. Epub 2011 Jan 14. Review.

30.

Overlap and effective size of the human CD8+ T cell receptor repertoire.

Robins HS, Srivastava SK, Campregher PV, Turtle CJ, Andriesen J, Riddell SR, Carlson CS, Warren EH.

Sci Transl Med. 2010 Sep 1;2(47):47ra64. doi: 10.1126/scitranslmed.3001442.

31.

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR.

Blood. 2010 Nov 25;116(22):4532-41. doi: 10.1182/blood-2010-05-283309. Epub 2010 Aug 11.

32.

Artificial antigen-presenting cells for use in adoptive immunotherapy.

Turtle CJ, Riddell SR.

Cancer J. 2010 Jul-Aug;16(4):374-81. doi: 10.1097/PPO.0b013e3181eb33a6. Review.

33.

A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy.

Turtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR.

Immunity. 2009 Nov 20;31(5):834-44. doi: 10.1016/j.immuni.2009.09.015. Epub 2009 Oct 29.

34.

Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit.

Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, Delaney C.

Blood. 2010 Jan 28;115(4):757-65. doi: 10.1182/blood-2009-07-228999. Epub 2009 Oct 12.

35.

Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.

Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS.

Blood. 2009 Nov 5;114(19):4099-107. doi: 10.1182/blood-2009-04-217604. Epub 2009 Aug 25.

36.

Adoptive transfer of virus-specific and tumor-specific T cell immunity.

Berger C, Turtle CJ, Jensen MC, Riddell SR.

Curr Opin Immunol. 2009 Apr;21(2):224-32. doi: 10.1016/j.coi.2009.02.010. Epub 2009 Mar 21. Review.

37.

Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus.

Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, Spies T, Groh V.

J Exp Med. 2009 Apr 13;206(4):793-805. doi: 10.1084/jem.20081648. Epub 2009 Mar 16.

38.

Clinical-scale elutriation as a means of enriching antigen-presenting cells and manipulating alloreactivity.

Micklethwaite KP, Garvin FM, Kariotis MR, Yee LL, Hansen AM, Antonenas V, Sartor MM, Turtle CJ, Gottlieb DJ.

Cytotherapy. 2009;11(2):218-28. doi: 10.1080/14653240802702160.

PMID:
19242837
39.

Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma.

Vari F, Munster DJ, Hsu JL, Rossetti TR, Mahler SM, Gray PP, Turtle CJ, Prue RL, Hart DN.

Br J Haematol. 2008 Nov;143(3):374-7. doi: 10.1111/j.1365-2141.2008.07346.x. Epub 2008 Aug 20.

PMID:
18729856
41.

Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapy.

Radford KJ, Turtle CJ, Kassianos AJ, Vuckovic S, Gardiner D, Khalil D, Taylor K, Wright S, Gill D, Hart DN.

J Immunother. 2005 Jul-Aug;28(4):322-31.

PMID:
16000950
42.

The immune response to breast cancer, and the case for DC immunotherapy.

Allan CP, Turtle CJ, Mainwaring PN, Pyke C, Hart DN.

Cytotherapy. 2004;6(2):154-63. Review.

PMID:
15203992
43.

DC in multiple myeloma immunotherapy.

Turtle CJ, Brown RD, Joshua DE, Hart DN.

Cytotherapy. 2004;6(2):128-37. Review.

PMID:
15203989
44.

Dendritic cells in tumor immunology and immunotherapy.

Turtle CJ, Hart DN.

Curr Drug Targets. 2004 Jan;5(1):17-39. Review.

PMID:
14738216
45.

Single step enrichment of blood dendritic cells by positive immunoselection.

López JA, Bioley G, Turtle CJ, Pinzón-Charry A, Ho CS, Vuckovic S, Crosbie G, Gilleece M, Jackson DC, Munster D, Hart DN.

J Immunol Methods. 2003 Mar 1;274(1-2):47-61.

PMID:
12609532
46.

Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression.

Vuckovic S, Kim M, Khalil D, Turtle CJ, Crosbie GV, Williams N, Brown L, Williams K, Kelly C, Stravos P, Rodwell R, Hill GR, Wright S, Taylor K, Gill D, Marlton P, Bradstock K, Hart DN.

Blood. 2003 Mar 15;101(6):2314-7. Epub 2002 Oct 24.

47.

Q-fever associated with splenic infarction and an anti-cardiolipin antibody.

Turtle CJ, Coyle LA, Kotsiou G.

Aust N Z J Med. 1999 Oct;29(5):755-6. No abstract available.

PMID:
10630667
48.

Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancer.

Turtle CJ, Keefe DM, Bell D, Wheeler H, Ma DD.

Aust N Z J Med. 1999 Apr;29(2):275-7. No abstract available.

PMID:
10342033

Supplemental Content

Loading ...
Support Center